Natural compounds represent approximately 35% of the pharmaceutical market, gaining prominence in the treatment of various diseases. Among them is chrysin, a flavonoid with notable antimicrobial and immunomodulatory activities. However, its low aqueous solubility and chemical instability limit its therapeutic use, highlighting the need for more soluble pharmaceutical carriers or derivatives, as well as patent analysis to map technologies and therapeutic development opportunities. Therefore, this study aimed to identify and explore trends in therapeutic strategies related to the action of chrysin and its derivatives in different pathologies, as well as their potential to increase clinical efficacy through pharmaceutical technologies. A technological survey was conducted on 36 patents registered between 1999 and 2025 in different databases. The analysis revealed peaks in patent applications in 2019 and 2024, with China as the main country and universities as the primary type of applicant. The patents demonstrated that chrysin and its derivatives exhibit complex immunological and pharmacological activities, acting on multiple cellular targets and signaling pathways. These include the inhibition of enzymes and proteins, modulation of inflammatory pathways, gene regulation, and other mechanisms. This pharmacological diversity of chrysin reinforces its relevance in patent applications, proving its efficacy and enabling new applications or therapeutic combinations.
Cézar et al. (Thu,) studied this question.